Pricing Log in Create free account
Saturday 31 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,415.16 41.46 +3.02%
Market cap
$1.29T
P/E
47.5×
Fwd P/E
36.7×
Dividend yield
0.47%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Eli Lilly and Company (LLY) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 2 removed · 22 modified
P2I1A: no material changes, the filing says
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 10 added · 3 removed · 21 modified
P2I1A: no material changes, the filing says
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 20, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 4, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 9 added · 10 removed · 61 modified
1A: 11 added · 2 removed · 60 modified
7: 16 added · 39 removed · 39 modified
8-K Feb 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 1, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 14, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 2, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.